yahoo_financeOriginal article
AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
Phase 3negativeNegative
AI Analysis
Summary
AstraZeneca's breast-cancer drug failed to meet its primary endpoint in a late-stage clinical trial. The failure represents a setback for the company's oncology pipeline.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
missed primary goal in late-stage trial
Importance:7/10
Sentiment:
-0.80
oncologybreast cancerPhase 3 failureclinical trial
Related Companies
Read the original article
Published by yahoo_finance on September 14, 2026 6:02 AM